# reload+after+2024-01-21 18:43:21.591183
address1§3150 Almaden Expressway
address2§Suite 250
city§San Jose
state§CA
zip§95118
country§United States
phone§408 708 9808
website§https://www.anixa.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
fullTimeEmployees§4
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Amit  Kumar Ph.D.', 'age': 59, 'title': 'Chairman & CEO', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 1071033, 'exercisedValue': 0, 'unexercisedValue': 6887334}, {'maxAge': 1, 'name': 'Mr. Michael J. Catelani CPA, MBA', 'age': 56, 'title': 'President, COO, CFO & Corporate Secretary', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 550958, 'exercisedValue': 0, 'unexercisedValue': 2755359}, {'maxAge': 1, 'name': 'Mr. John  Roop', 'age': 73, 'title': 'Senior Vice President of Engineering', 'yearBorn': 1950, 'fiscalYear': 2022, 'totalPay': 275000, 'exercisedValue': 0, 'unexercisedValue': 4556}, {'maxAge': 1, 'name': 'Dr. Pamela D. Garzone Ph.D.', 'age': 68, 'title': 'Chief Development Officer & Chair Breast Cancer Clinical Advisory Board', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.006
priceToSalesTrailing12Months§581.4529
currency§USD
dateShortInterest§1702598400
forwardEps§-0.37
exchange§NCM
quoteType§EQUITY
shortName§Anixa Biosciences, Inc.
longName§Anixa Biosciences, Inc.
firstTradeDateEpochUtc§434381400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d1a6c561-efcb-3db9-b4a0-d18906465c04
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.0
targetLowPrice§12.0
targetMeanPrice§12.0
targetMedianPrice§12.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§13.93
grossMargins§0.23333
ebitdaMargins§0.0
trailingPegRatio§None
